In patients with NAFLD, mRNA expression of genes involved in fatty acid oxidation, such as LCAD, HADHα, CYP2E1, and CYP4A11, is increased while that of CPT1A and PPARA is decreased compared with that in the livers of normal individuals [21, 37]. The gene discussed is CPT1A; the disease is metabolic dysfunction-associated steatotic liver disease.